Our analysis indicates that although inhibition of STATs is said to severely hinder the viability of certain cancers, combinatorial therapy of STATs alongside other key proteins including TP53, ESR1 and EGFR may result in a higher degree of success especially in solid cancers. Here, TP53 is linked to cancer.